Researchers say gene, protein and microbiome signals show real differences between patients, but drug choice still rests on factors like kidney health, cost and tolerability.
Recap by typeshit. Full story at BIOENGINEER.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
BusinessWorld Online covers a Lilly weight loss drug still in clinical trials. Few details were given beyond the headline.
A short social post says drugs like Ozempic may lower heart attack and stroke risk, possibly beyond what weight loss alone explains.
In a JAMA Network Open survey study of 3,615 adults, GLP-1 use was 20.5% with a cancer history versus 26.5% without, about 30% lower odds.
Novo Nordisk shared the figure from a post-trial analysis of its next-generation experimental drug, with results broken out for women.
Loading…